CSTL Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of -29.38% compared to Castle Biosciences's net margin of 5.4%. Castle Biosciences's return on equity of -1.17% beat Delcath Systems's return on equity of -40.28%.

Castle Biosciences has a consensus price target of $35.89, signalling upside risk potential of 92.13%. On the other hand Delcath Systems has an analysts' consensus of $24.08 which suggests that it could grow by 114.03%. Given that Delcath Systems has higher upside potential than Castle Biosciences, analysts believe Delcath Systems is more attractive than Castle Biosciences.

Castle Biosciences has a beta of 1.103, which suggesting that the stock is 10.345% more volatile than S&P 500. In comparison Delcath Systems has a beta of 0.871, suggesting its less volatile than the S&P 500 by 12.874%.

Castle Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

Castle Biosciences quarterly revenues are $88M, which are larger than Delcath Systems quarterly revenues of $19.8M. Castle Biosciences's net income of -$25.8M is lower than Delcath Systems's net income of $1.1M. Notably, Castle Biosciences's price-to-earnings ratio is 30.24x while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences is 1.58x versus 6.91x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

Exact Sciences has a net margin of -29.38% compared to Castle Biosciences's net margin of -14.32%. Castle Biosciences's return on equity of -1.17% beat Exact Sciences's return on equity of -35.57%.

Castle Biosciences has a consensus price target of $35.89, signalling upside risk potential of 92.13%. On the other hand Exact Sciences has an analysts' consensus of $68.54 which suggests that it could grow by 27.7%. Given that Castle Biosciences has higher upside potential than Exact Sciences, analysts believe Castle Biosciences is more attractive than Exact Sciences.

Castle Biosciences has a beta of 1.103, which suggesting that the stock is 10.345% more volatile than S&P 500. In comparison Exact Sciences has a beta of 0.950, suggesting its less volatile than the S&P 500 by 5%.

Castle Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

Castle Biosciences quarterly revenues are $88M, which are smaller than Exact Sciences quarterly revenues of $706.8M. Castle Biosciences's net income of -$25.8M is higher than Exact Sciences's net income of -$101.2M. Notably, Castle Biosciences's price-to-earnings ratio is 30.24x while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences is 1.58x versus 3.52x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Illumina has a net margin of -29.38% compared to Castle Biosciences's net margin of 12.58%. Castle Biosciences's return on equity of -1.17% beat Illumina's return on equity of -34.38%.

Castle Biosciences has a consensus price target of $35.89, signalling upside risk potential of 92.13%. On the other hand Illumina has an analysts' consensus of $108.36 which suggests that it could grow by 11.76%. Given that Castle Biosciences has higher upside potential than Illumina, analysts believe Castle Biosciences is more attractive than Illumina.

Castle Biosciences has a beta of 1.103, which suggesting that the stock is 10.345% more volatile than S&P 500. In comparison Illumina has a beta of 1.359, suggesting its more volatile than the S&P 500 by 35.899%.

Castle Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences pays -- of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend.

Castle Biosciences quarterly revenues are $88M, which are smaller than Illumina quarterly revenues of $1B. Castle Biosciences's net income of -$25.8M is lower than Illumina's net income of $131M. Notably, Castle Biosciences's price-to-earnings ratio is 30.24x while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences is 1.58x versus 3.56x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of -29.38% compared to Castle Biosciences's net margin of -9.1%. Castle Biosciences's return on equity of -1.17% beat Star Equity Holdings's return on equity of -15.99%.

Castle Biosciences has a consensus price target of $35.89, signalling upside risk potential of 92.13%. On the other hand Star Equity Holdings has an analysts' consensus of $8.50 which suggests that it could grow by 331.47%. Given that Star Equity Holdings has higher upside potential than Castle Biosciences, analysts believe Star Equity Holdings is more attractive than Castle Biosciences.

Castle Biosciences has a beta of 1.103, which suggesting that the stock is 10.345% more volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.934, suggesting its less volatile than the S&P 500 by 6.616%.

Castle Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

Castle Biosciences quarterly revenues are $88M, which are larger than Star Equity Holdings quarterly revenues of $12.9M. Castle Biosciences's net income of -$25.8M is lower than Star Equity Holdings's net income of -$1.2M. Notably, Castle Biosciences's price-to-earnings ratio is 30.24x while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences is 1.58x versus 0.11x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.